Youkadi to Present Long-Term Clinical Data of U16 (CD20 CAR-T) and Preclinical Insights on Target Antigen-Expressing T Cells at ASH 2024

Recently, UniCAR-Therapy announced that the long-term follow-up clinical data of its proprietary product U16 injection and the basic research data on target antigen-expressing T cells will be presented at the 66th American Society of Hematology (“ASH”) Annual Meeting, which will take place from December 7 to 10, 2024. The above abstract has been published on the ASH official website.

Target Antigen-Expressing T Cells Facilitate CAR-T Cell Eradication of Residual CD19+B Malignant Cells (Target antigen-expressing T cells assist CAR-T cells in eliminating CD19+) B Residual Malignant Cells)

Number: 4794

Collaborating Units: SHANGHAI UNICAR-THERAPY BIOMED-PHAMACEUTICAL TECHNOLOGY CO., LTD, First Affiliated Hospital of Soochow University, Collaborative Innovation Center for Hematology of Soochow University, Shanghai Biomedical Science and Technology Industrial Promotion Center, Shanghai Center for Drug Evaluation and Inspection

Presentation Time: Monday, December 9, 2024, 6:00 PM - 8:00 PM (PST) / Tuesday, December 10, 2024, 10:00 AM - 12:00 AM (Beijing Time)

Abstract link:https://ash.confex.com/ash/2024/webprogram/Paper206406.html

This study proposes the hypothesis that CAR-T cell activation depends on the concentration of target antigen, which can be stimulated by using target antigen-expressing T cells (TAET) to further activate CAR-T cells and eliminate CD19+ cells.New Treatment Strategies for B Malignant Cell Residuals. Based on this hypothesis, the research team innovatively designed an in vitro model to evaluate the impact of target cell quantity on CAR-T cell activation and an in vivo mouse model that simulates minimal residual disease (MRD) in clinical settings. The results from these two models collectively demonstrate that the immune response of anti-CD19 CAR-T cells is dependent on the dose of the target antigen and will only be activated when the threshold level of target cells is reached. In cases where the number of residual tumor cells is limited, infusing anti-CD19 CAR-T cells while supplementing with CD19+ cells is recommended.TAET cells can restore the anti-tumor ability of CD19 CAR-T cells and promote deep clearance of residual tumor cells. Therefore, in cases of low tumor burden, CD19+ can be used as an adjuvant when CAR-T is reinfused.TAET cells can significantly enhance the ability of CAR-T cells to deeply eliminate tumor cells, bringing long-term benefits to patients.

About UNICAR-THERAPY

SHANGHAI UNICAR-THERAPY BIOMED-PHAMACEUTICAL TECHNOLOGY CO., LTD ("UNICAR-therapy" for short) is a leading biopharmaceutical company dedicated to the innovation and translation of cutting-edge cell therapy technologies, possessing several original core technology platforms, including the SMART small nucleotide gene regulation empowerment technology platform, MADDS antibody innovative drugability technology platform, 6H production quality control platform, etc. Currently, the company has established a billion-level gene and cell therapy research and industrial center in the North Shanghai Biomedical Park, creating an internationally first-class immune treatment tumor innovation technology translation center and an advanced, high-end genetically engineered immune cell industry chain center. UNICAR-therapy has successfully treated thousands of advanced cancer patients through cooperation with many well-known medical institutions at home and abroad. UNICAR-therapy boasts a rich product pipeline, including autologous CAR-T technology, universal CAR-T technology, and in vivo CAR technology, covering indications such as hematological tumors, solid tumors, and autoimmune diseases. Currently, three first-in-class/first-in-safe products are in the registration clinical research stage. ssCART-19 injection can be used as a breakthrough treatment for CAR-T contraindicated central nervous system leukemia (commonly known as "brain white"), has obtained FDA orphan drug designation, been included in the NMPA breakthrough therapy list, and entered the critical clinical stage; U16 injection is a non-CD19 target lymphoma treatment product with significant efficacy and will soon enter the critical clinical stage; U87 injection is a fully human CAR-T product, with proposed indications covering various malignant tumors such as lung cancer, triple-negative breast cancer, pancreatic cancer, nasopharyngeal cancer, and colorectal cancer, currently in Phase I of the registration clinical trial.